INSIDER
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Daily Brief03Live04Congress05Corporate Insiders06Government Money07Political Influence08Institutions09Washington Network10Follow the Power11Disclosure Clock12AI Investigator13Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 431m ago
HOUSE PTR30m ago
SEC 13F30m ago
ROBINHOOD CHAIN30m ago
Corporate insider
FJ

Fitzgerald Kevin Joseph

CSO & EVP, Head of ResearchCIK 0001886431

EDGAR filingsOpen in network
Disclosed transactions29
Buys / sells0 / 27
Max Insider Score23
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
FJ
Fitzgerald Kevin JosephDirector
OVIDOvid Therapeutics Inc.
Grant or award
A$45K
17.6K sh
Apr 7, 2026Apr 9, 2026
traded Apr 7, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    Ovid Therapeutics Inc.Director · Apr 9, 2026
  • Insider ofevidence
    ALNYLAM PHARMACEUTICALS, INC.CSO & EVP, Head of Research · Jan 14, 2026
9
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Grant or award · 10b5-1 plan
A
—
3,800 sh
Jan 11, 2026
Jan 14, 2026
traded Jan 11, 2026
+3d
SEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$56K
155 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$73K
199 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

23
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$80K
220 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$72K
197 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$207K
562 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$238K
644 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$180K
485 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

16
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$104K
280 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence

13
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$46K
122 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC FORM 4

Evidence